Inventiva SA
IVAHealthcare|Biotechnology|France
$4.29
-0.21 (-4.66%)
About
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Stock Price
+27.1%(1Y)
Pipeline Summary
8 total trials1
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
Completed: 6Recruiting: 1Active: 1
Active Trials (2)
Global Research Initiative for Patients Screening on MASH
NCT05651724MASH
Recruiting
Enrollment: 10,000 participants
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Phase 3Active
Enrollment: 1,000 participants
BioScore
4.7/10
Cautious
Ownership
Data last updated: Jul 13, 2026, 12:48 PM